Delivery Order SPE2DB20D2104-SPE2DB22FS13M
- Not listed
- This federal contract award was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $2,237.22 firm-fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a cardiovascular medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,353.62 firm-fixed-price delivery order is for the supply of the medication MULTAQ 400 MG TABLET 60S. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This single-award IDC serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,289.16 firm-fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a cardiovascular medication. This award falls under a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical. The IDC, which runs through November 2026, serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $25,747.81 firm fixed-price delivery order is for the pharmaceutical product MULTAQ 400 MG TABLET 60S. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This single-award IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of MULTAQ 400 MG TABLET 60S. The $1,499.38 firm fixed-price delivery order falls under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of MULTAQ 400 MG TABLET 60S. The firm-fixed-price delivery order, valued at $2,236.10, falls under a larger Indefinite Delivery Contract (IDC) with Cencora, Inc. (doing business as Amerisourcebergen) worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,065.40 Firm Fixed Price Delivery Order covers the supply of MULTAQ 400 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of December 4, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $1,405.87 firm fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a medication used for cardiovascular health. The contract has an ultimate completion date of April 21, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which has significant experience providing pharmaceutical...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $10,061.38 firm fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $4,718.66 firm fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a pharmaceutical product. The contract has a period of performance through March 13, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FS13MDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,766.10 firm fixed-price delivery order is for the supply of MULTAQ 400 MG TABLET 60S, a cardiovascular medication. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense globally. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Cencora, Inc. also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs demonstrate the company's capacity to meet the diverse pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 3/18/22 |